Evidence map›Paper›PMID 31929967›Full record

ArticleQuantitative imaging in medicine and surgery2019

Percutaneous cryoablation for the treatment of liver cancer at special sites: an assessment of efficacy and safety.

Jianbing Ma, Fuming Wang, Weiqiang Zhang, Lizhang Wang, Xiaofeng Yang, Ying Qian, Jianjun Huang, Jia Wang, Jijin Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Quantitative imaging in medicine and surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jianbing MaDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Fuming WangDepartment of Interventional Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
Weiqiang ZhangDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Lizhang WangDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Xiaofeng YangDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Ying QianDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Jianjun HuangDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Jia WangDepartment of Radiology, the First Affiliated Hospital, College of Medicine, Jiaxing University, Jiaxing 314000, China.
Jijin YangDepartment of Interventional Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
First Hospital of Jiaxing · CNChanghai Hospital · CNJiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the safety and efficacy of cryoablation (CA) devices for the treatment of liver cancer at special sites in a retrospective study.

methodsSpecial site liver cancer was defined as the tumors directly abutting surrounding structures (such as the liver capsule, gallbladder, vessel, diaphragm, intestine, and adrenal gland) with a maximum distance of 1.0 cm between the tumor and these organs. Sixty-six patients (49 men, 17 women; mean age, 60.8 years; age range, 27-82 years) were included. CA procedure was performed to treat 69 tumors under the guidance of computed tomography or ultrasound. Local tumor progression was assessed during the follow-up. A visual analog scale (VAS) evaluated the pain degree. Complications were assessed during and after every procedure.

resultsThe number of tumors under the liver capsule and adjacent to the gallbladder, portal or hepatic vein, diaphragm, intestine, and adrenal gland were 29, 5, 8, 14, 7, and 6, respectively. The median follow-up time was 14 months (range, 2-28 months). In the 69 procedures, the technical success rate was 100%. The cumulative local tumor progression rates at 6, 9, 15, and 24 months were 10.2%, 16.5%, 20.9%, and 30.5%, respectively. No cases of serious complications occurred. During operation, the occurrence rates of subcapsular hemorrhage and pneumothorax were 2.9% and 1.4%, respectively. After the operation, the occurrence rate of biloma, capsular injury, subcapsular planting metastasis, and pneumothorax were 1.4%, 18.8%, 1.4%, and 2.8%, respectively. The average score of 66 patients with a VAS was 2.15±0.63 during the operation.

conclusionsPercutaneous CA is safe and effective for patients with special site liver cancer.

Indexed as

cancercryoablation (CA)LiverMR

Identifiers

PMID31929967
PMCPMC6942968
OpenAlexW2993452467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.